Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-31

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry study is to gather real world standard of care (SOC) data on the safety and performance on the Roxwood Medical catheter devices in the treatment of stenotic lesions and CTO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study

NCT00801710

Coronary Artery Disease Coronary Artery Chronic Total Occlusion

COMPLETED NA

Prospective Study of the SoundBite™ Crossing System in Complex Peripheral CTOs

NCT03933657

Peripheral Arterial Occlusive Disease Chronic Total Occlusion of Artery of the Extremities

WITHDRAWN NA

Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures

NCT06795763

Coronary Chronic Total Occlusions Ischemic Heart Disease Ischemic Heart Disease (IHD) +1 more

ENROLLING_BY_INVITATION NA

RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers

NCT02818972

Aortic Aneurysm, Thoracic Penetrating Ulcer

ACTIVE_NOT_RECRUITING NA

The Asahi Intecc PTCA Chronic Total Occlusion Study

NCT02379923

Coronary Artery Disease Coronary Artery Chronic Total Occlusion

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Roxwood Anchoring Catheters are a group of artery catheters used in participants undergoing interventional procedures. These anchoring catheters are support catheters used in conjunction with guidewires to access discrete regions of the coronary and peripheral vasculature. They may be used to facilitate placement and exchange of guidewires and/or other interventional devices beyond stenotic lesions, including CTOs. The goal of this registry study is to collect prospective observational data on the performance of the Roxwood CenterCross™, CenterCross™ Ultra, CenterCross™ Ultra LV, MultiCross™, and MicroCross™ 14, 14ES and 18 MicroCatheter devices through 24 hours and the safety of the devices through 30 days in native coronary and peripheral arteries with a stenotic lesion or CTO. Additionally, the catheters will be evaluated for the ability to facilitate a guidewire successfully penetrating the proximal cap of the stenotic lesion or CTO and the infusion of saline and contrast agents as confirmed by angiography.

Of the 100 intended participants to be treated, it is anticipated that at least 50 participants will be enrolled and treated using the Roxwood MicroCross™ 14, 14ES and/or 18 MicroCatheter and 50 participants will be enrolled and treated using the CenterCross™, CenterCross™ Ultra, CenterCross™ Ultra LV, and/or MultiCross™ devices.

Adverse Events will be coded according to Medical Dictionary for Regulatory Activities (MedDRA). Data from the study will be collected via electronic data capture (EDC). Clinical data will be extracted in the desired format by the BTG Data Management from the EDC on an ongoing basis to support data review activities. An independent monitor will visit the investigational site and review the Electronic Case Report Forms (eCRFs). Data entered in the EDC will be immediately saved to a central database and changes tracked to provide an audit trail.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Total Occlusion Atherosclerosis Coronary Artery Disease Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Roxwood Anchoring Catheters

Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.

Roxwood Anchoring Catheters

Intervention Type DEVICE

Anchoring catheters

Acetylsalicylic Acid

Intervention Type DRUG

Oral Tablet

Heparin

Intervention Type DRUG

Intravenous Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Roxwood Anchoring Catheters

Anchoring catheters

Intervention Type DEVICE

Acetylsalicylic Acid

Oral Tablet

Intervention Type DRUG

Heparin

Intravenous Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Roxwood CenterCross™ Catheter - 125 centimeters (cm) working length CenterCross™ ULTRA Catheter - 125 cm working length CenterCross™ ULTRA LV Catheter - 100 cm working length MultiCross™ Catheter - 135 cm working length MicroCross™ 14 Microcatheter- 135 cm working length MicroCross™ 14 Microcatheter - 155 cm working length MicroCross™ 14ES Extra Support Microcatheter - 135 cm working length MicroCross™ 18 Microcatheter - 90 cm working length MicroCross™ 18 Microcatheter - 135 cm working length MicroCross™ 18 Microcatheter - 155 cm working length Aspirin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Roxwood CenterCross™, CenterCross™ Ultra, CenterCross™® Ultra LV, MultiCross™ and MicroCross™ 14, 14ES and 18 MicroCatheter device(s) used in first attempts at crossing the stenotic lesion or CTO
* CTO lesion \>3 months
* Thrombolysis in myocardial infarction (TIMI) 0 or 1
* Coronary lesion of at least 2.5 millimeter (mm) in diameter
* Native arterial lesions only
* Peripheral lesions no minimum diameter or length
* Adult aged 25 - 80
* Participant understands and has signed the study informed consent form
* Left ventricle ejection fraction \>25% (coronary enrollments only)

Exclusion Criteria

* Endovascular revascularization or surgical revascularization of target lesion within \<30 days of procedure
* Prior attempted CTO revascularization (during same procedure)
* Participant unable to give informed consent
* Elevated creatine kinase-muscle/brain (CK-MB) or Troponin levels at baseline
* Participant is known or suspected to be unable to tolerate the contrast agent even with pre-treatment
* CTO is located in aorto-ostial location, saphenous vein graft (SVG), or in-stent
* Appearance of a fresh thrombus or intraluminal filling defects
* Intolerance to Aspirin and/or the inability to tolerate a second antiplatelet agent (Clopidogrel, Prasugrel, Ticagrelor)
* Severe renal insufficiency with estimated glomerular filtration rate (eGFR) \<30 milliliters/ minute (mL/min)/1.72 meter squared (m\^2)
* Congestive heart failure \[New York Heart Association (NYHA) Class III\\IV\] CSA Class IV
* Life expectancy \<6 months due to other illnesses
* Vascular graft
* Women with a positive pregnancy test
* Nitinol or nickel allergy
* Transplanted heart
* Acute or unstable medical disorder/disease that may cause a risk to participant, including:

* Recent myocardial infarction (MI) \<30 days
* Significant anemia (for example, hemoglobin \<8.0 milligram/deciliter (mg/dL)
* Recent major cerebrovascular event (history of stroke or transient ischemic attack \[TIA\] within \<30 days)
* Severe uncontrolled systemic hypertension (for example, \>180/100 millimeter of mercury \[mmHg\])
* Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) \<30 days

Minimum Eligible Age

25 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No